You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 16, 2024

OCTREOTIDE ACETATE - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for octreotide acetate and what is the scope of patent protection?

Octreotide acetate is the generic ingredient in six branded drugs marketed by Chiesi, Fresenius Kabi Usa, Gland Pharma Ltd, Heritage Pharms, Meitheal, Sagent Pharms Inc, Shuangcheng, Sun Pharm Inds, Teva Pharms Usa Inc, West-ward Pharms Int, Wockhardt Usa, Mylan Institutional, and Novartis, and is included in twenty-five NDAs. There are thirteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Octreotide acetate has sixty-three patent family members in twenty-five countries.

There are nineteen drug master file entries for octreotide acetate. Ten suppliers are listed for this compound.

Summary for OCTREOTIDE ACETATE
Drug Prices for OCTREOTIDE ACETATE

See drug prices for OCTREOTIDE ACETATE

Recent Clinical Trials for OCTREOTIDE ACETATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Phase 1
Albert Einstein College of MedicinePhase 1
Columbia UniversityPhase 1

See all OCTREOTIDE ACETATE clinical trials

Pharmacology for OCTREOTIDE ACETATE
Medical Subject Heading (MeSH) Categories for OCTREOTIDE ACETATE
Paragraph IV (Patent) Challenges for OCTREOTIDE ACETATE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
MYCAPSSA Delayed-release Capsules octreotide acetate 20 mg 208232 1 2023-12-29
SANDOSTATIN Injection octreotide acetate 0.05 mg/mL (base), 0.1 mg/mL (base) and 0.5 mg/mL (base) packaged in 1 mL pre-filled syringes (preservative-free) 019667 1 2008-01-17

US Patents and Regulatory Information for OCTREOTIDE ACETATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fresenius Kabi Usa OCTREOTIDE ACETATE (PRESERVATIVE FREE) octreotide acetate INJECTABLE;INJECTION 077457-002 Feb 10, 2006 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Chiesi MYCAPSSA octreotide acetate CAPSULE, DELAYED RELEASE;ORAL 208232-001 Jun 26, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Shuangcheng OCTREOTIDE ACETATE octreotide acetate INJECTABLE;INJECTION 217860-001 May 2, 2024 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sagent Pharms Inc OCTREOTIDE ACETATE octreotide acetate INJECTABLE;INJECTION 091041-002 Nov 12, 2013 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
West-ward Pharms Int OCTREOTIDE ACETATE (PRESERVATIVE FREE) octreotide acetate INJECTABLE;INJECTION 076313-001 Mar 28, 2005 AP RX No Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Wockhardt Usa OCTREOTIDE ACETATE octreotide acetate INJECTABLE;INJECTION 090986-001 May 11, 2011 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for OCTREOTIDE ACETATE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis SANDOSTATIN LAR octreotide acetate INJECTABLE;INJECTION 021008-001 Nov 25, 1998 ⤷  Sign Up ⤷  Sign Up
Novartis SANDOSTATIN LAR octreotide acetate INJECTABLE;INJECTION 021008-002 Nov 25, 1998 ⤷  Sign Up ⤷  Sign Up
Novartis SANDOSTATIN LAR octreotide acetate INJECTABLE;INJECTION 021008-003 Nov 25, 1998 ⤷  Sign Up ⤷  Sign Up
Novartis SANDOSTATIN octreotide acetate INJECTABLE;INJECTION 019667-002 Oct 21, 1988 ⤷  Sign Up ⤷  Sign Up
Novartis SANDOSTATIN LAR octreotide acetate INJECTABLE;INJECTION 021008-002 Nov 25, 1998 ⤷  Sign Up ⤷  Sign Up
Novartis SANDOSTATIN octreotide acetate INJECTABLE;INJECTION 019667-004 Jun 12, 1991 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for OCTREOTIDE ACETATE

Country Patent Number Title Estimated Expiration
Japan 2021050240 医薬組成物および関連する送達方法 (PHARMACEUTICAL COMPOSITION, AND RELATED DELIVERY METHOD) ⤷  Sign Up
South Korea 101814186 ⤷  Sign Up
Hong Kong 1143072 ENHANCED BIOAVAILABILITY OF OCTREOTIDE VIS THE GI TRACT USING A SUSPENSION IN A HYDROPHOBIC MEDIUM ⤷  Sign Up
New Zealand 591810 PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF DELIVERY THE COMPOSITION COMPRISES A MEDIUM CHAIN FATTY ACID ⤷  Sign Up
Israel 276157 תכשירי רוקחות ושיטות להעברתם הקשורות להן (Pharmaceutical compositions and related methods of delivery) ⤷  Sign Up
United Kingdom 0916349 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.